

CLAIMS

- Sub a2
1. In a particulate drug delivery composition for intranasal delivery comprising a plurality of bioadhesive microspheres and a systemically active drug, the improvement comprising that at least 90 wt % of the microspheres of the composition have a diameter of between 0.1 μm and 10 μm .
 2. A drug delivery composition according to Claim 1 wherein the microspheres are prepared from a material that will gel in contact with the mucosal surface.
 3. A drug delivery composition according to Claim 1 or 2 wherein the microspheres comprise starch, starch derivatives, gelatin, albumin, collagen, dextran or dextran derivatives.
 4. A drug delivery composition according to Claim 3 wherein the microspheres are starch microspheres.
 5. A drug delivery composition according to Claim 1 wherein the microsphere material is cross-linked.
 6. A drug delivery composition according to Claim 1 wherein the microspheres have been stabilised by heat treatment.
 7. A drug delivery composition according to Claim 1 additionally comprising an absorption enhancer.
 8. A drug delivery composition according to Claim 7 wherein the absorption enhancer is a surfactant, a lysophosphatidylcholine or a lysophosphatidylglycerol.
- Sub a3
- Sub a4
- Sub a5

9. A drug delivery composition according to Claim 1 wherein the drug is a biologically active peptide.

10. A drug delivery composition according to Claim 9 wherein the peptide
5 is insulin or calcitonin.

11. A system for intranasal drug delivery comprising a drug delivery composition according to Claim 1 and a container having an orifice through which the composition can be delivered to the nasal mucosa in a gas stream.

10

12. A system according to Claim 11 wherein the system is such that, in use, the product of the flow rate and the square of the microsphere aerodynamic diameter is greater than $2000 \mu\text{m}^2 \cdot \text{litres/min}$.

15 13. A method of delivering a drug to the nasal mucosa, comprising introducing a gas stream containing a composition according Claim 1 into the nose.

20 14. A method of treating diabetes comprising introducing a gas stream containing a composition according to Claim 1 wherein the systemically active drug is insulin into the nose.

Add a⁶7

08877273.061797
262790. E224880